The Latest Breaking News from AstraZeneca

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new COVID vaccine. VLA2001 is manufactured by French pharmaceutical company Valneva for use in the UK and was approved on April 14 for use in adults between the ages of 18 and 50 for first and second doses.

It is the sixth Covid-19 vaccine to be granted an MHRA authorisation for use in Britain

India has begun offering booster doses of COVID-19 vaccine to all adults but is limiting free shots at government centers to front-line workers and people over age 60

The Centre for Covid-19 Situation Administration (CCSA) has approved a plan to procure a long-acting coronavirus antibody cocktail for people with poor immune systems who cannot be vaccinated.

Harbour BioMed has announced a global out-license agreement with AstraZeneca plc (NASDAQ:AZN) for CLDN18.2xCD3 bispecific antibody (HBM7022). HBM7022 is a novel bispecific antibody generated from HBM's HCAb Based Immune Cell Engagers (HBICE) Platform.  HBM7022 is currently in the preclinical stage, which crosslinks tumor cells and T cells by targeting a tumor-associated antigen (Claudin18.2) and…

Here's a roundup of top developments in the biotech space over the last 24 hours:

AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 4.32% on an annualized basis producing an average annual return of 18.01%. Currently, AstraZeneca has a market capitalization of $214.04 billion.

AstraZeneca Plc (NASDAQ:AZN) shared new and prolonged follow-up results from the Phase 3 CHAMPION-MG trial open-label extension (OLE) of Ultomiris (ravulizumab-cwvz) in generalized myasthenia gravis (gMG). Ultomiris demonstrated long-term efficacy, with improvements in activities of daily living, muscle strength, and quality of life sustained through 60 weeks. Ultomiris was also well tolerated throughout…

During the second half of 2021, Scott was the top recipient of drug campaign cash in Congress